Loading...
Glenmark Pharmaceuticals Limited — Bortezomib Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #8 for Bortezomib · $150.0K export value · DGFT Verified
Glenmark Pharmaceuticals Limited is the #8 Indian exporter of Bortezomib with $150.0K in export value and 3 verified shipments. Glenmark Pharmaceuticals Limited holds a 0.7% market share in Bortezomib exports across 2 countries. The company exports 28 pharmaceutical products worth $205.5M across 14 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $4.5M | 90 | 32.6% |
| BRAZIL | $2.9M | 58 | 21.0% |
| BELGIUM | $871.4K | 20 | 6.3% |
| GERMANY | $821.9K | 82 | 6.0% |
| MEXICO | $698.6K | 45 | 5.1% |
| ISRAEL | $650.0K | 13 | 4.7% |
| PHILIPPINES | $508.9K | 31 | 3.7% |
| CANADA | $500.0K | 10 | 3.6% |
| MALTA | $438.2K | 25 | 3.2% |
| UNITED KINGDOM | $436.0K | 18 | 3.2% |
India exports Bortezomib to 109 countries. The top destination is UNITED STATES (32.6%), followed by BRAZIL and BELGIUM.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| YUSEN LOGISTICS BENELUX BELGIUM | BELGIUM | $871.4K | 20 |
| EUGIA US LLC, | UNITED STATES | $650.0K | 13 |
| FRESENIUS KABI DEUTSCHLAND GMBH | GERMANY | $609.5K | 66 |
| EUGIA US LLC | UNITED STATES | $450.0K | 9 |
| EVERSANA LIFE SCIENCE SERVICES LLC | UNITED STATES | $300.0K | 6 |
India exported $13.7M worth of Bortezomib through 1,383 shipments from 200 suppliers to 109 countries, serving 498 buyers globally. Glenmark Pharmaceuticals Limited contributes $150.0K to this total, accounting for 0.7% of India's Bortezomib exports.
Glenmark Pharmaceuticals Limited's average Bortezomib shipment value is $50.0K per consignment, based on 3 shipments totaling $150.0K.
Glenmark Pharmaceuticals Limited ranks #8 among 200 Indian Bortezomib exporters with a 0.7% market share. The top 3 exporters are MSN LABORATORIES PRIVATE LIMITED ($3.6M), EUGIA PHARMA SPECIALITIES LIMITED ($3.5M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($2.9M). Glenmark Pharmaceuticals Limited processed 3 shipments to 2 destination countries.
What Glenmark Pharmaceuticals Limited must comply with to export Bortezomib to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #8 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 10 | GLAND PHARMA LIMITED | $200.0K | 4 | 2 | $50.0K |
| 11 | VEXXA LIFESCIENCES PVT. LTD. | $166.6K | 14 | 1 | $11.9K |
| 8 | GLENMARK PHARMACEUTICALS LIMITED ★ | $150.0K | 3 | 2 | $50.0K |
| 12 | UNITED BIOTECH PRIVATE LIMITED | $143.6K | 19 | 4 | $7.6K |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 263 | 19.0% |
| SAHAR AIR | 229 | 16.6% |
| DELHI AIR CARGO ACC (INDEL4) | 168 | 12.1% |
| DELHI AIR | 148 | 10.7% |
| HYDERABAD ACC (INHYD4) | 82 | 5.9% |
| HYDERABAD AIR | 82 | 5.9% |
| Bombay Air | 62 | 4.5% |
| Bombay Air Cargo | 32 | 2.3% |
Glenmark's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, causing increased freight costs and extended transit times. These challenges are particularly impactful for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management. (pharmaceuticalcommerce.com)
Conversely, the US-China trade tensions have opened avenues for Indian pharmaceutical companies like Glenmark to expand their footprint in the US market. The shifting trade dynamics have prompted US importers to seek alternative suppliers, presenting growth opportunities for Indian exporters.
The recent India-European Union Free Trade Agreement (FTA) is poised to benefit Glenmark by eliminating tariffs on pharmaceutical exports to the EU. This development enhances the company's competitiveness in the European market, potentially boosting export volumes and revenue streams. (en.wikipedia.org)
Compliance with international regulatory standards is paramount for Glenmark's export success. The company has consistently adhered to guidelines set by the US FDA, WHO, and EU GMP, ensuring the quality and safety of its products. Notably, Glenmark's manufacturing facilities have undergone rigorous inspections, reflecting its commitment to maintaining high-quality standards.
The evolving regulatory landscape, including the EU's Falsified Medicines Directive, necessitates continuous adaptation. Glenmark's proactive approach to compliance positions it well to navigate these changes, thereby sustaining its market access and reputation.
Glenmark Pharmaceuticals Limited exports 28 products worth $205.5M. Beyond Bortezomib, top products include Rosuvastatin, Omeprazole, Gabapentin, Ondansetron, Naproxen. View the complete Glenmark Pharmaceuticals Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Bortezomib — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Glenmark Pharmaceuticals Limited's Bortezomib exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Glenmark Pharmaceuticals Limited
Full Company Profile →
28 products · $205.5M total trade · 14 categories
| MEDISON PHARMA | ISRAEL | $300.0K | 6 |
| SUN FARMACUTICA DO BRASIL LTDA | BRAZIL | $200.0K | 4 |
| AUROLOGISTICS LLC (AUROMEDICS PHARM | UNITED STATES | $200.0K | 4 |
| SUN FARMACUTICA DO BRASIL LIMITEDA | BRAZIL | $150.0K | 3 |
| SUN FARMACEUTICA DO BRAZIL LTDA. | BRAZIL | $100.0K | 2 |
India's Bortezomib is purchased by 498 buyers worldwide. The top buyer is YUSEN LOGISTICS BENELUX BELGIUM (BELGIUM), followed by EUGIA US LLC, and FRESENIUS KABI DEUTSCHLAND GMBH.
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 13 | MILES INTERNATIONAL | $129.4K | 28 | 3 | $4.6K |
Glenmark Pharmaceuticals Limited ranks #8 among 200 Indian Bortezomib exporters. Average shipment value of $50.0K compared to the market average of $68.4K. The closest competitors by value are GLAND PHARMA LIMITED and VEXXA LIFESCIENCES PVT. LTD..
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 109+ countries, 498+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Glenmark Pharmaceuticals Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Bortezomib. For current shipment-level data, contact TransData Nexus.